PriceTargets.com logo

Knight Therapeutics - KHTRF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.55
  • Forecasted Upside: 79.45%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.65 As of 03/21/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for KHTRF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Knight Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KHTRF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KHTRF

Analyst Price Target is $6.55
▲ +79.45% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is $6.55, with a high forecast of $7.50 and a low forecast of $5.40. The average price target represents a 79.45% upside from the last price of $3.65.

This chart shows the closing price for KHTRF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Knight Therapeutics. This rating has held steady since September 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/15/2022Stifel NicolausBoost TargetC$5.30 ➝ C$5.40
5/13/2022Knight EquityLower TargetC$7.00 ➝ C$6.75
3/25/2022Raymond JamesLower TargetC$8.50 ➝ C$7.50
3/25/2022Knight EquityLower TargetC$8.00 ➝ C$7.00
3/25/2022Stifel NicolausDowngradeBuy ➝ HoldC$7.00 ➝ C$5.30
11/15/2021Stifel NicolausBoost TargetBuyC$6.50 ➝ C$7.00
9/23/2021Stifel EuropeUpgradeHold ➝ BuyC$5.95 ➝ C$6.50
4/26/2021KCGBoost TargetOutperform$6.75 ➝ $7.75
4/26/2021Cannonball ResearchReiterated RatingBuy
4/26/2021Raymond JamesReiterated RatingOutperform
4/26/2021Knight EquityBoost TargetOutperform$6.75 ➝ $7.75
11/16/2020KCGLower TargetOutperform$8.25 ➝ $6.75
11/16/2020Knight EquityLower TargetOutperform$8.25 ➝ $6.75
8/13/2020Stifel NicolausInitiated CoverageBuy$10.50
6/23/2020Stifel NicolausReiterated RatingBuy$10.50
10/9/2019Raymond JamesSet TargetBuy$10.30
4/5/2019Paradigm CapitalReiterated RatingHold
1/16/2019Raymond JamesReiterated RatingBuy
(Data available from 3/22/2018 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Knight Therapeutics logo
Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: $3.65
Low: $3.65
High: $3.65

50 Day Range

MA: $3.84
Low: $3.65
High: $3.96

52 Week Range

Now: $3.65
Low: $3.65
High: $4.77

Volume

N/A

Average Volume

2,700 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Knight Therapeutics?

The following equities research analysts have issued reports on Knight Therapeutics in the last twelve months: Knight Equity, Raymond James, and Stifel Nicolaus.
View the latest analyst ratings for KHTRF.

What is the current price target for Knight Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Knight Therapeutics in the last year. Their average twelve-month price target is $6.55, suggesting a possible upside of 79.5%. Raymond James has the highest price target set, predicting KHTRF will reach $7.50 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $5.40 for Knight Therapeutics in the next year.
View the latest price targets for KHTRF.

What is the current consensus analyst rating for Knight Therapeutics?

Knight Therapeutics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KHTRF, but not buy more shares or sell existing shares.
View the latest ratings for KHTRF.

What other companies compete with Knight Therapeutics?

Other companies that are similar to Knight Therapeutics include 1933 Industries, 4Front Ventures, AB Science, Abacus Health Products and Acreage. Learn More about companies similar to Knight Therapeutics.

How do I contact Knight Therapeutics' investor relations team?

Knight Therapeutics' physical mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The company's listed phone number is (514) 484-4483. The official website for Knight Therapeutics is www.gud-knight.com. Learn More about contacing Knight Therapeutics investor relations.